Ozempic and Wegovy linked to rare risk of sudden vision loss
A study by Rutgers researchers has identified a potential link between GLP-1 receptor agonist medications, such as Ozempic and Wegovy, and a rare eye condition called ischemic optic neuropathy. While the risk increase is small, the study highlights the importance of monitoring side effects as these drugs become more widely used for weight loss and diabetes.
Why it matters
Given the massive popularity of these medications, identifying even rare side effects is critical for patient safety and medical guidance.
A large study led by Rutgers researchers has identified a possible vision risk associated with widely used diabetes and weight loss medications, including Ozempic and Wegovy. The findings suggest that people taking these drugs may face a slightly higher risk of developing a rare eye condition that can cause sudden and potentially permanent vision loss.
The condition, known as ischemic optic neuropathy, occurs when blood flow to the optic nerve is reduced. Because the optic nerve carries visual information from the eye to the brain, damage to it can lead to significant vision problems.
Study Links GLP-1 Drugs to Rare Vision Loss
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in